+

PE20080425A1 - Formulacion aerosol para la inhalacion de beta-agonistas - Google Patents

Formulacion aerosol para la inhalacion de beta-agonistas

Info

Publication number
PE20080425A1
PE20080425A1 PE2007001122A PE2007001122A PE20080425A1 PE 20080425 A1 PE20080425 A1 PE 20080425A1 PE 2007001122 A PE2007001122 A PE 2007001122A PE 2007001122 A PE2007001122 A PE 2007001122A PE 20080425 A1 PE20080425 A1 PE 20080425A1
Authority
PE
Peru
Prior art keywords
beta
alkyl
agonists
inhalation
aerosol formulation
Prior art date
Application number
PE2007001122A
Other languages
English (en)
Inventor
Michael Nowak
Michael Aven
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38564599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080425(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20080425A1 publication Critical patent/PE20080425A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN BETA-AGONISTA DE FORMULA (1) DONDE R1 Y R2 SON CADA UNO H, HALOGENO, ALQUILO(C1-C4) O JUNTOS FORMAN ALQUILENO(C1-C6); R3 ES H, HALOGENO, OH, ALQUILO(C1-C4) U O-ALQUILO; X- ES UN ANION TAL COMO CLORURO, BROMURO, SULFATO, ACETATO, ENTRE OTROS; B) CLORURO DE BENZALCONIO EN UNA CANTIDAD DE 1 A 50MG POR 100ML DE SOLUCION; C) UN FORMADOR DE COMPLEJOS EN UNA CANTIDAD DE 1 A 50MG POR 100ML DE SOLUCION; D) UN DISOLVENTE TAL COMO AGUA, ETANOL O UNA MEZCLA DE LOS MISMOS EN DONDE EL ETANOL SE ENCUENTRA DE 5% A 99%; E) UN ANTIOXIDANTE TAL COMO ACIDO ASCORBICO, PROPILGALATO, ENTRE OTROS. DICHA COMPOSICION TIENE UN pH DE 2,5 A 6,5 SIENDO UTIL PARA EL TRATAMIENTO DE ENFISEMA PULMONAR, ASMA, FIBROSIS QUISTICA, BRONQUITIS
PE2007001122A 2006-08-22 2007-08-20 Formulacion aerosol para la inhalacion de beta-agonistas PE20080425A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06119274 2006-08-22

Publications (1)

Publication Number Publication Date
PE20080425A1 true PE20080425A1 (es) 2008-06-16

Family

ID=38564599

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001122A PE20080425A1 (es) 2006-08-22 2007-08-20 Formulacion aerosol para la inhalacion de beta-agonistas

Country Status (9)

Country Link
US (1) US20080053430A1 (es)
EP (1) EP2056837A1 (es)
JP (1) JP2010501523A (es)
AR (1) AR062477A1 (es)
CA (1) CA2661442A1 (es)
PE (1) PE20080425A1 (es)
TW (1) TW200820974A (es)
UY (1) UY30555A1 (es)
WO (1) WO2008023005A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005008921A1 (de) * 2005-02-24 2006-08-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
US7423146B2 (en) * 2005-11-09 2008-09-09 Boehringer Ingelheim International Gmbh Process for the manufacturing of pharmaceutically active 3,1-benzoxazine-2-ones
PE20080610A1 (es) * 2006-08-22 2008-07-15 Boehringer Ingelheim Int Nuevos beta-agonistas enantiomericamente puros, procedimientos para su preparacion y uso como medicamentos
EP2093219A1 (de) 2008-02-22 2009-08-26 Boehringer Ingelheim International Gmbh Kristalline, enantiomerenreine Salzform eines Betamimetikums und dessen Verwendung als Arzneimittel
CN102362262B (zh) * 2009-03-24 2014-06-25 雪佛龙美国公司 用于表征地下储油层中的裂面的系统和方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3026534A1 (de) * 1980-07-12 1982-03-18 C.H. Boehringer Sohn, 6507 Ingelheim 3,1-benzoxazin-2-one, ihre herstellung und verwendung
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
DE102005008921A1 (de) * 2005-02-24 2006-08-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
US7423146B2 (en) * 2005-11-09 2008-09-09 Boehringer Ingelheim International Gmbh Process for the manufacturing of pharmaceutically active 3,1-benzoxazine-2-ones
PE20080610A1 (es) * 2006-08-22 2008-07-15 Boehringer Ingelheim Int Nuevos beta-agonistas enantiomericamente puros, procedimientos para su preparacion y uso como medicamentos

Also Published As

Publication number Publication date
WO2008023005A1 (de) 2008-02-28
UY30555A1 (es) 2008-03-31
TW200820974A (en) 2008-05-16
AR062477A1 (es) 2008-11-12
EP2056837A1 (de) 2009-05-13
US20080053430A1 (en) 2008-03-06
JP2010501523A (ja) 2010-01-21
CA2661442A1 (en) 2008-02-28

Similar Documents

Publication Publication Date Title
PE20080425A1 (es) Formulacion aerosol para la inhalacion de beta-agonistas
HRP20171614T1 (hr) Heterociklički spojevi, lijekovi koji sadrže te spojeve, njihova primjena i postupci za njihovu proizvodnju
ES2579936T3 (es) Nuevos lípidos catiónicos con diversos grupos de cabeza para el suministro oligonucleotídico
MEP51008A (en) Aerosol formulation for inhalation, containing an anticholinergic agent
ES2314408T3 (es) Formulaciones de hfc en solucion que contienen un anticolinergico.
PE20120023A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
AR050902A1 (es) Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
NO20062877L (no) Stabile liposomsammensetninger som omfatter lipofile aminholdige farmasoytiske midler
AR062104A1 (es) Derivados de quinuclidina como antagonistas de m3
NZ621981A (en) Lipid compositions
EP2735343A1 (en) Fire extinguishing agent and fire extinguishing method using same
UY26570A1 (es) Carboxamidas de pirimidina útiles como inhibidores de isozimas pde4
NZ606893A (en) Amine and amine oxide surfactants for controlling herbicide spray drift
PE20090698A1 (es) Derivados de alcoholes de 1-fenil-2-piridinilalquilo como inhibidores de la fosfodiesterasa
NO20054839L (no) Formulering for en oppmalt-dose inhalator ved anvendelse av hydro-fluor-alkaner som drivmidler
MX2010010832A (es) Formulacion acuosa estable que contiene esporas.
TW200730197A (en) Hair cosmetic composition
AR035431A1 (es) 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas, un metodo para su sintesis, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos
CN103446943B (zh) 双子型全氟烷基磺酰氧基苄基阳离子表面活性剂及其制备与应用
AR063854A1 (es) Beta-1,6-disacaridos de glucosamina funcionalizados y un procedimiento para su preparacion. composiciones farmaceuticas
BRPI0514058A (pt) composições para limpeza de substratos microeletrÈnicos
BRPI0417268A (pt) benzimidazóis que contêm morfolinila, como inibidores da replicação de vìrus sinciciais respiratórios
EA202090979A1 (ru) Композиции на основе дикамбы с уменьшенным потенциальным сносом при опрыскивании
CN103464049B (zh) 全氟己基磺酰氧基苄基阳离子表面活性剂及其制备方法与应用
AR046114A1 (es) Compuesto de 8- azoniabiciclo (3.2.1) octano, composicion farmaceutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarinicos y uso del compuesto para preparar dicha composicion

Legal Events

Date Code Title Description
FD Application declared void or lapsed
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载